Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,618 across all filing types
Latest filing 2025-03-23 Major Shareholding Noti…
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Change in substantial holding 3 pages 167.9KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 604 filed under the Corporations Act 2001, specifically a "Notice of change of interests of substantial holder." It details changes in voting power and shareholdings of a substantial shareholder (BVF Partners L.P. and associates) in Syntara Limited. The document includes dates of changes, voting power percentages, and particulars of relevant interests in voting securities. This type of filing is a notification of changes in significant share ownership levels, which corresponds to the category of Major Shareholding Notification (MRQ). The document is substantive and not merely an announcement or certification, and it does not fit other categories such as director dealings or capital changes. Therefore, the correct classification is MRQ with high confidence.
2025-03-23 English
Acceleration of skin scarring program 4 pages 246.0KB
Capital/Financing Update Classification · 95% confidence The document is a media release from Syntara Limited announcing the acceleration of their skin scarring program with a new drug candidate SNT-9465. It details the clinical trial plans, scientific background, and strategic outlook for the drug development program. The content focuses on a product development update and clinical trial initiation rather than financial results, regulatory filings, or shareholder meeting materials. It is not an earnings release, annual report, or regulatory filing. It is a corporate announcement about a clinical development program and strategic update, which fits best under the category of Capital/Financing Update (CAP) as it relates to company development programs and investment in clinical trials. The document length is substantial and contains detailed information about the clinical trial design and company strategy, supporting a confident classification as CAP rather than a brief announcement or regulatory filing.
2025-03-17 English
Skin scarring webinar featuring Professor Fiona Wood 2 pages 192.7KB
Regulatory Filings Classification · 95% confidence The document is a media release announcing an investor webinar about recent developments in the company's skin scarring program. It includes details about the webinar timing, speakers, registration link, and company background. There are no financial statements, earnings data, or detailed financial analysis present. The document is essentially an announcement of an event (investor webinar) rather than a financial report or detailed investor presentation. It does not fit into categories like Earnings Release, Annual Report, or Investor Presentation. Given the nature of the content as a public announcement to investors about a webinar, the most appropriate classification is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements and communications that do not fit other categories.
2025-03-17 English
Change of Director's Interest Notice - HDS 3 pages 282.1KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in the director's relevant interests in securities, including the number of shares held before and after the change, the nature of the change, and the value of the transaction. This type of document is a formal notification of personal share transactions by a company director, commonly known as a director's dealing notice. It does not contain financial performance data, management discussion, or other report content. Therefore, it fits the category of Director's Dealing (DIRS). The document length and content confirm it is not a brief announcement or a report publication notice but a substantive notification of insider trading activity.
2025-03-13 English
Syntara to present at NWR Virtual Healthcare Conference 2 pages 191.8KB
Investor Presentation Classification · 85% confidence The document is a media release announcing that Syntara Limited will present at the NWR Virtual Healthcare Conference on a specific date. It includes details about the presentation, how to register, and information about the company and its drug development pipeline. There is no financial data, no detailed investor presentation content, no earnings or annual report information, and no regulatory filing or certification. The document is essentially an announcement of an upcoming investor presentation event rather than the presentation itself. Therefore, the most appropriate classification is Investor Presentation (IP), as it relates to a detailed presentation for investors focusing on financials, strategy, and market position, even though the actual presentation content is not included, the announcement is about the presentation event itself which fits best under IP rather than RPA or RNS.
2025-03-13 English
Half Year Report and Appendix 4D 26 pages 2.0MB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Syntara Limited Appendix 4D Half-year report' and covers the half-year ended 31 December 2024. It includes detailed financial results such as revenues, losses, net tangible assets, and dividends information. It also contains a directors' report, auditor's review report, and comprehensive financial statements including profit or loss, financial position, changes in equity, cash flows, and notes. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement. The content and structure align with an Interim / Quarterly Report, which is a comprehensive financial report for a period shorter than a full fiscal year and contains substantive financial data and analysis. Therefore, the document should be classified as an Interim / Quarterly Report (IR).
2025-02-25 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.